<PAGE> 1
---------------------------
OMB APPROVAL
---------------------------
OMB Number: 3235-0145
Expires: August 31, 1999
Estimated average burden
hours per response..14.90
---------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 2)*
AVIRON
-----------------------------------------------
(Name of Issuer)
Common Stock
------------------------------
(Title of Class of Securities)
053762100
---------------------------------------
(CUSIP Number)
12/31/98
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[ ] Rule 13d-1(c)
[X] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF INFORMATION CONTAINED
IN THIS FORM ARE NOT REQUIRED TO RESPOND UNLESS THE FORM DISPLAYS A CURRENTLY
VALID OMB CONTROL NUMBER.
Page 1 of 4
<PAGE> 2
----------------------- ---------------------------
CUSIP NO. 053762100 13G PAGE 2 OF 4 PAGES
----------------------- ---------------------------
--------- ---------------------------------------------------------------------
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO(S). OF ABOVE PERSON(S) (ENTITIES ONLY)
Sang - A Pharm. Co. Ltd.
--------- ---------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)
(b)
--------- ---------------------------------------------------------------------
3 SEC USE ONLY
--------- ---------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
South Korea
--------- ---------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 239,200
--- --------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 0
--- --------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
REPORTING 239,200
--- --------------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
WITH: 0
--------- ---------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
239,200
--------- ---------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
--------- ---------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
1.52%
--------- ---------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
00
--------- ---------------------------------------------------------------------
*SEE INSTRUCTION BEFORE FILLING OUT!
Page 2 of 4
<PAGE> 3
ITEM 1.
(a) Name of Issuer
Aviron
(b) Address of Issuer's Principal Executive Offices
297 North Bernardo Ave.
Mountain View, CA 94043
ITEM 2.
(a) Name of Person Filing
Sang - A Pharm. Co. Ltd.
(b) Address of Principal Business Office or, if none, Residence
1628-26 Seocho-dong
Seocho-gu
Seoul, Korea
(c) Citizenship
South Korea
(d) Title of Class of Securities
Common Stock
(e) CUSIP Number
053762100
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTIONS 240.13d-1(b), OR
240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:
N/A
ITEM 4. OWNERSHIP
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount Beneficially Owned: 239,200
(b) Percent of Class: 1.52%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 239,200
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the disposition
of: 239,200
(iv) Shared power to dispose or to direct the disposition
of: 0
Instruction: For computations regarding securities which represent a right to
acquire an underlying security see Section 240.13d-3(d)(1).
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more than
five percent of the class of securities, check the following |X|.
Instruction: Dissolution of a group requires a response to this item.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
N/A
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
N/A
Page 3 of 4
<PAGE> 4
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
N/A
ITEM 8. NOTICE OF DISSOLUTION OF A GROUP
N/A
ITEM 9. CERTIFICATION
(a) The following certification shall be included if the statement
is filed pursuant to Section 240.13d-1(b):
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were acquired and are
held in the ordinary course of business and were not acquired
and are not held for the purpose of or with the effect of
changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose
or effect.
(b) The following certification shall be included if the statement
is filed pursuant to Section 240.13d-1(c):
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing
or influencing the control of the issuer of the securities and
were not acquired and are not held in connection with or as a
participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 22, 1999
-----------------------------------
Date
/s/ Alan C. Mendelson
-----------------------------------
Signature
Alan C. Mendelson, Attorney-in-fact
-----------------------------------
Name/Title
Page 4 of 4
